Disease · MONDO_0019558

discoid lupus erythematosus

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. discoid lupus erythematosus. Diseases, record MONDO_0019558. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0019558

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: discoid lupus erythematosus; Open Targets
Open Targets ID: MONDO_0019558; Open Targets
Other names: DLE; Open Targets
MeSH: D008179; MeSH
NCI Thesaurus: C26820; NCI Thesaurus
Orphanet: ORPHA:90281; Orphanet
Highest stage of its drugs: Phase 2, for 14 of its 20 drugs, from ClinicalTrials.gov and TTD; Open Targets

Drugs20

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ETANERCEPT	CHEMBL1201572	Protein	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
LEVOSALBUTAMOL	CHEMBL1002	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
RUXOLITINIB	CHEMBL1789941	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
DAXDILIMAB	CHEMBL4594330	Antibody	Phase 2	ClinicalTrials.gov and TTD	2	1	1	Drugs and targets
TANZISERTIB	CHEMBL1950289	Small molecule	Phase 2	ClinicalTrials.gov and TTD	2	1	1	Drugs and targets
ARTENIMOL	CHEMBL307261	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
DELGOCITINIB	CHEMBL4297507	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
DEUCRAVACITINIB	CHEMBL4435170	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
DOVRAMILAST	CHEMBL4297460	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
EFALIZUMAB	CHEMBL1201575	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 20

See all 20 drugs

Targets27

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
JAK3	Janus Kinase (JAK)	4	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK3 inhibitor	Phase 2	https://conductscience.org/library/genes/3718	Drugs and targets
TYK2	Janus Kinase (JAK)	4	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase TYK2 inhibitor; Tyrosine-protein kinase TYK2 negative allosteric modulator	Phase 2	https://conductscience.org/library/genes/7297	Drugs and targets
JAK1	Janus Kinase (JAK)	3	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK1 inhibitor	Phase 2	https://conductscience.org/library/genes/3716	Drugs and targets
JAK2	Janus Kinase (JAK)	3	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK2 inhibitor	Phase 2	https://conductscience.org/library/genes/3717	Drugs and targets
PDE4A	Phosphodiesterase 4	2	Phosphodiesterase 4 inhibitor	Phase 2	https://conductscience.org/library/genes/5141	Drugs and targets
PDE4B	Phosphodiesterase 4	2	Phosphodiesterase 4 inhibitor	Phase 2	https://conductscience.org/library/genes/5142	Drugs and targets
PDE4C	Phosphodiesterase 4	2	Phosphodiesterase 4 inhibitor	Phase 2	https://conductscience.org/library/genes/5143	Drugs and targets
PDE4D	Phosphodiesterase 4	2	Phosphodiesterase 4 inhibitor	Phase 2	https://conductscience.org/library/genes/5144	Drugs and targets
ADRB2	Beta-2 adrenergic receptor	1	Beta-2 adrenergic receptor agonist	Phase 2	https://conductscience.org/library/genes/154	Drugs and targets
CRBN	CRL4(CRBN) E3 ubiquitin ligase	1	CRL4(CRBN) E3 ubiquitin ligase inhibitor	Phase 2	https://conductscience.org/library/genes/51185	Drugs and targets

1 to 10 of 27

See all 27 targets

Trials23

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT04857034	A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)	Phase 2	74	2025-09-10	Lupus Erythematosus, Discoid, Lupus Erythematosus, Subacute Cutaneous	DEUCRAVACITINIB	Its record names the disease	ClinicalTrials.gov
NCT01597050	Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions	Phase 2	54	2016-06-08	Lupus Erythematosus, Discoid, Lupus Erythematosus, Systemic	R-333	Its record names the disease	ClinicalTrials.gov
NCT03958955	Efficacy and Safety of Delgocitinib Cream in Discoid Lupus Erythematosus.	Phase 2	27	2021-06-28	Discoid Lupus Erythematosus	DELGOCITINIB	Its record names the disease	ClinicalTrials.gov
NCT04908280	Study of Ruxolitinib Cream for the Treatment of Discoid Lupus Erythematosus	Phase 2	10	2025-05-20	Discoid Lupus Erythematosus	RUXOLITINIB	Its record names the disease	ClinicalTrials.gov
NCT00708916	Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus Patients	Phase 1/2	8	2021-03-03	Discoid Lupus Erythematosus	APREMILAST	Its record names the disease	ClinicalTrials.gov
NCT05540327	The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)	Phase 2	381		Systemic Lupus Erythematosus	ENPATORAN	Its record names the disease	ClinicalTrials.gov
NCT07557927	A Multicentre, Randomised, Double-blind, Positive-control Clinical Trial Evaluating Dihydroartemisinin Tablets for the Treatment of Discoid Lupus Erythematosus	Phase 2	100		Discoid Lupus Erythematosus	ARTENIMOL	Its record names the disease	ClinicalTrials.gov
NCT05591222	Study of Daxdilimab (HZN-7734) in Participants With Moderate-to-Severe Primary Discoid Lupus Erythematosus	Phase 2	72		Discoid Lupus Erythematosus	DAXDILIMAB	Its record names the disease	ClinicalTrials.gov
NCT05362188	Topical Nicotinamide in Treatment of DLE	Early phase 1	60		Discoid Lupus Erythematosus	NIACINAMIDE	Its record names the disease	ClinicalTrials.gov
NCT01300208	To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus	Phase 2	48		Cutaneous Lupus Erythematosus	DOVRAMILAST	Its record names the disease	ClinicalTrials.gov

1 to 10 of 23

See all 23 trials

Comparisons in its trials1

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial
Drug: R932333 vs Placebo: serious adverse events	0 of 36	0 of 18	54	NCT01597050

Source Trial comparisons

Papers from its trials2

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
33687069	DERIVED	2	PubMed
28118537	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0019558

GET https://conductscience.org/api/diseases/v1/MONDO_0019558/targets?page=2

API reference For AI assistants